CN105189486A - 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用 - Google Patents

苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用 Download PDF

Info

Publication number
CN105189486A
CN105189486A CN201480016601.XA CN201480016601A CN105189486A CN 105189486 A CN105189486 A CN 105189486A CN 201480016601 A CN201480016601 A CN 201480016601A CN 105189486 A CN105189486 A CN 105189486A
Authority
CN
China
Prior art keywords
acid
oxo
isomer
pharmaceutically acceptable
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480016601.XA
Other languages
English (en)
Other versions
CN105189486B (zh
Inventor
姚其正
刘佳佳
王朝辉
吴奎
王永彬
姚世宁
陈瑞环
杨贝贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUODA BIOSCIENCES Inc
Original Assignee
LUODA BIOSCIENCES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LUODA BIOSCIENCES Inc filed Critical LUODA BIOSCIENCES Inc
Priority to CN201480016601.XA priority Critical patent/CN105189486B/zh
Publication of CN105189486A publication Critical patent/CN105189486A/zh
Application granted granted Critical
Publication of CN105189486B publication Critical patent/CN105189486B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dispersion Chemistry (AREA)

Abstract

本申请公开了一种氧代靛玉红或异靛蓝衍生物、以及氧代氮杂靛玉红的衍生物，以及其光学异构体、外消旋体、顺反异构体和药学上可接受的盐，其可以用于制备预防或治疗如糖代谢紊乱、炎性和自身免疫性疾病、神经退化性疾病、精神性疾病、组织增生性疾病或肿瘤等疾病的药物。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201480016601.XA 2013-05-28 2014-05-26 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用 Active CN105189486B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480016601.XA CN105189486B (zh) 2013-05-28 2014-05-26 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013102020293 2013-05-28
CN201310202029.3A CN103333161B (zh) 2013-05-28 2013-05-28 1’-氧代靛玉红的制备和用途
PCT/CN2014/000525 WO2014190758A1 (zh) 2013-05-28 2014-05-26 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用
CN201480016601.XA CN105189486B (zh) 2013-05-28 2014-05-26 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用

Publications (2)

Publication Number Publication Date
CN105189486A true CN105189486A (zh) 2015-12-23
CN105189486B CN105189486B (zh) 2018-07-31

Family

ID=49241382

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310202029.3A Expired - Fee Related CN103333161B (zh) 2013-05-28 2013-05-28 1’-氧代靛玉红的制备和用途
CN201480016601.XA Active CN105189486B (zh) 2013-05-28 2014-05-26 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310202029.3A Expired - Fee Related CN103333161B (zh) 2013-05-28 2013-05-28 1’-氧代靛玉红的制备和用途

Country Status (10)

Country Link
US (1) US9868734B2 (zh)
EP (1) EP3006442A4 (zh)
JP (1) JP2016519167A (zh)
KR (1) KR20160012984A (zh)
CN (2) CN103333161B (zh)
AU (1) AU2014273751A1 (zh)
CA (1) CA2912943A1 (zh)
MX (1) MX2015016217A (zh)
RU (1) RU2015140611A (zh)
WO (1) WO2014190758A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CN108721279B (zh) * 2017-04-19 2021-06-29 安尼根有限公司 包含5′-羟基-5-硝基-靛玉红-3′-肟作为活性成分的乳腺癌治疗剂
CN106946760A (zh) * 2017-04-28 2017-07-14 遵义医学院 靛玉红衍生物或药学上能接受的盐用于抗肿瘤药物及制备方法
CN111233741B (zh) * 2020-03-04 2021-04-16 大连理工大学 一种有机催化靛红自缩合制备异靛蓝类化合物的方法
US20230174548A1 (en) * 2020-03-19 2023-06-08 Board Of Regents Of The University Of Nebraska Symbiotic prodrugs for the treatment of cancer and other diseases
CN113072540B (zh) * 2021-03-29 2023-07-14 贵州医科大学 一种靛玉红衍生的降解剂及其制备与应用
WO2023090935A1 (ko) * 2021-11-18 2023-05-25 애니젠 주식회사 뉴클레오린에 특이적으로 결합하는 agm 펩타이드를 제조하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324355A (zh) * 1998-10-22 2001-11-28 西巴特殊化学品控股有限公司 氧代苯并呋喃亚基－二氢吲哚酮
CN101747339A (zh) * 2009-11-25 2010-06-23 上海交通大学 1′-硫代氮杂靛玉红类化合物、用途及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609022B2 (ja) * 1981-06-19 1985-03-07 イスクラ産業株式会社 インジルビン誘導体およびそれを含有する抗腫瘍剤
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
DK1079826T3 (da) * 1998-05-29 2003-06-23 Centre Nat Rech Scient Anvendelse af indigoide bisindolderivater til fremstilling af et medikament til inhibering af cyclinafhængige kinaser
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
CN1378447A (zh) * 1999-04-12 2002-11-06 海恩兹·赫伯特·菲比格 穿透细胞膜的靛类双吲哚衍生物的用途
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20100098702A1 (en) * 2008-09-16 2010-04-22 Longgui Wang Method of treating androgen independent prostate cancer
CA2469649C (en) * 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
CN1199946C (zh) * 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
JP5448455B2 (ja) * 2005-12-23 2014-03-19 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） 新規３’−，７−置換インジルビンおよびそれらの適用
CN101023944A (zh) 2006-02-23 2007-08-29 黎明涛 靛玉红衍生物在制备治疗神经退行性变疾病药物中的应用
CN101314584A (zh) * 2007-05-28 2008-12-03 中国人民解放军军事医学科学院放射与辐射医学研究所 HGF/c-Met信号通道抑制剂及其制备方法和用途
CN101074229B (zh) * 2007-06-08 2010-09-01 无锡杰西医药科技有限公司 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途
EP2379549B1 (en) 2008-12-22 2016-09-21 Eisenbrand, Gerhard 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
EP2199292A1 (en) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
CN101492410B (zh) * 2009-03-05 2011-06-22 上海交通大学 用于抗肿瘤药物的靛玉红类化合物
CN101492465A (zh) 2009-03-05 2009-07-29 上海交通大学 用于抗肿瘤药物的7，7＇-二氮杂靛玉红类化合物
CN101492448B (zh) 2009-03-05 2012-09-19 上海交通大学 用于抗肿瘤药物的7＇-氮杂靛玉红类化合物
CN101704813B (zh) 2009-11-25 2011-11-16 上海交通大学 1′-硫代靛玉红类化合物、用途及其制备方法
KR101180030B1 (ko) * 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
US9051306B2 (en) * 2011-07-15 2015-06-09 Nihon University Indirubin derivative having highly selective cytotoxicity for malignant tumors
CN103333161B (zh) 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CN103627748B (zh) * 2013-11-21 2016-03-30 华侨大学 一种靛玉红衍生物的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324355A (zh) * 1998-10-22 2001-11-28 西巴特殊化学品控股有限公司 氧代苯并呋喃亚基－二氢吲哚酮
CN101747339A (zh) * 2009-11-25 2010-06-23 上海交通大学 1′-硫代氮杂靛玉红类化合物、用途及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEFANIE LIBNOW: "《First synthesis of oxa-analogous isoindigo-N-glycosides》", 《TETRAHEDRON LETTERS》 *

Also Published As

Publication number Publication date
RU2015140611A (ru) 2017-07-04
CN103333161B (zh) 2015-09-30
CN103333161A (zh) 2013-10-02
EP3006442A1 (en) 2016-04-13
AU2014273751A1 (en) 2015-10-29
WO2014190758A1 (zh) 2014-12-04
JP2016519167A (ja) 2016-06-30
EP3006442A4 (en) 2017-03-08
CN105189486B (zh) 2018-07-31
US9868734B2 (en) 2018-01-16
MX2015016217A (es) 2016-03-01
KR20160012984A (ko) 2016-02-03
US20160185771A1 (en) 2016-06-30
CA2912943A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
CN105189486B (zh) 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用
Khoshneviszadeh et al. Design, synthesis and biological evaluation of novel anti-cytokine 1, 2, 4-triazine derivatives
AU2008261491B2 (en) Azaindole-indole coupled derivatives, preparation methods and uses thereof
Zhang et al. Synthesis and structure–activity relationships of N2-alkylated quaternary β-carbolines as novel antitumor agents
CN106167483B (zh) 可用于胆固醇动员的化合物、组合物和方法
Guo et al. Synthesis and structure-activity relationships of asymmetric dimeric β-carboline derivatives as potential antitumor agents
Shang et al. Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway
CN106831812B (zh) 含联芳基酰胺结构的杂环并嘧啶或吡嗪类化合物及其应用
WO2018022868A1 (en) Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant
CN106565685A (zh) 微管蛋白抑制剂
CN106083704A (zh) 3,5‑(E)‑ 二芳亚甲基‑N‑环丙基哌啶‑4‑酮类化合物作为Hsp90抑制剂的应用
JP6239103B2 (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
CN102746212B (zh) β-榄香烯吲哚衍生物及其制备和应用
Zha et al. Synthesis and in vitro anticancer evaluation of novel flavonoid-based amide derivatives as regulators of the PI3K/AKT signal pathway for TNBC treatment
CN113135938B (zh) 取代的大环类酪氨酸激酶抑制剂及其用途
CN104884456B (zh) PI3K和/或mTOR抑制剂
EP1433789A1 (en) Pyrrolopyrazines and their use as selective apoptosis inducers
RU2486184C2 (ru) Производные азаиндола-индола, способы их изготовления и использования
Darzi Synthesis and Evaluation of a New Class of Cancer Chemotherapeutics Based on Purine-like Extended Amidines
CN105061326A (zh) 一类哒嗪酮类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant